Combined Transcranial Magnetic Stimulation and Electroencephalography of the Dorsolateral Prefrontal Cortex
August 17th, 2018
15.8K views
The protocol presented here is for TMS-EEG studies utilizing intracortical excitability test-retest design paradigms. The intent of the protocol is to produce reliable and reproducible cortical excitability measures for assessing neurophysiological functioning related to therapeutic interventions in the treatment of neuropsychiatric diseases such as major depression.
Overview
This protocol describes a method for conducting TMS-EEG studies that assess intracortical excitability through a test-retest design. It aims to provide reliable measures for evaluating neurophysiological functions related to treatments for neuropsychiatric disorders, such as major depression.
Key Study Components
Area of Science
- Neuroscience
- Clinical neurophysiology
- Psychiatry
Background
- This study focuses on measuring cortical excitability.
- It seeks to understand predictors of response to therapeutic interventions.
- The protocol is designed to ensure reproducibility of measurements.
- It incorporates TMS and EEG for a comprehensive evaluation of brain functions.
Purpose of Study
- To develop reliable methods for assessing changes in cortical excitability.
- To aid in identifying neurophysiological signals related to therapeutic responses.
- To enhance the understanding of neurophysiological mechanisms in neuropsychiatric treatment.
Methods Used
- TMS-EEG as the primary method for measuring cortical excitability.
- The biological model involves participants with neuropsychiatric conditions.
- Proper electrode preparation, TMS coil calibration, and adjustment of stimulation intensity are critical components.
- Key steps include electrode placement, impedance checking, and controlling TMS parameters.
- Data is recorded during single-pulse and paired-pulse TMS procedures.
Main Results
- The method facilitates reliable monitoring of cortical excitability.
- Electrode preparation directly affects signal quality and measurement accuracy.
- Significant artifacts may occur during stimulation, necessitating careful coil placement adjustments.
- The study optimizes methods for capturing key neurophysiological responses.
Conclusions
- The study demonstrates a robust protocol for advancing TMS-EEG research in neuropsychiatry.
- It enables deeper insights into cortical excitability and its implications for treatment responses.
- The findings are relevant for understanding neuronal mechanisms and improving therapeutic approaches.
Frequently Asked Questions
What are the advantages of using TMS-EEG?
TMS-EEG combines the advantages of both TMS and EEG, allowing for real-time monitoring of cortical excitability and brain activity during stimulation.
How is the biological model implemented in the study?
Participants are selected based on neuropsychiatric conditions, and the TMS procedure is applied to measure changes in their cortical excitability.
What types of data are obtained from this protocol?
The protocol yields data on cortical excitability changes and neurophysiological responses during therapeutic interventions.
How can this method be adapted for different studies?
The method can be adapted by altering stimulation parameters or using different biological models depending on the research focus.
What are the key limitations of this protocol?
Limitations include the potential for artifacts during stimulation and the need for precise electrode placement to ensure accurate data collection.
Executive Industry Relevance
Combined TMS-EEG of the dorsolateral prefrontal cortex enables direct, quantitative assessment of cortical excitability and connectivity, supporting predictive biomarker development for neuropsychiatric intervention response. This reproducible, test-retest paradigm strengthens mechanistic de-risking and target validation at the interface of discovery and translational neuroscience. The approach is positioned to inform portfolio decisions by providing robust neurophysiological endpoints for early-stage therapeutic evaluation.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of cortical circuit function and target engagement in disease-relevant brain regions.
- Supports biological de-risking by quantifying neurophysiological changes linked to intervention.
- Facilitates predictive confidence in target modulation through reproducible, quantitative readouts.
Screening & Assay Development
- Prepares validated neurophysiological assays for downstream compound or device screening.
- Standardizes measurement of cortical excitability and connectivity for cross-study comparability.
- Enables reproducible, quantitative outputs suitable for screening readiness and platform reuse.
Translational & Preclinical Research
- Aligns neurophysiological endpoints with translational biomarker strategies for neuropsychiatric disorders.
- Provides continuity from discovery through preclinical validation by enabling test-retest reliability.
- Supports risk-adjusted advancement decisions based on mechanistic and functional readouts.
Pipeline & Workflow Integration
This method integrates from early discovery through translational research, bridging target validation, assay development, and preclinical biomarker alignment in neuropsychiatric R&D.
- Discovery Biology: Quantifies cortical excitability and connectivity to clarify mechanistic hypotheses.
- Screening: Delivers standardized, reproducible neurophysiological assays for intervention evaluation.
- Analytics: Provides quantitative EEG and TMS-evoked readouts for condition comparison and statistical analysis.
- Translational Research: Aligns with biomarker strategies for patient stratification and response prediction.
- Enterprise Reuse: Establishes a reusable platform for neurophysiological assessment across programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in neuropsychiatric target validation.
- Operational Value: Standardizes and scales neurophysiological measurements for reproducibility and cross-study integration.
- Strategic Value: Informs go/no-go decisions and enhances capital efficiency by providing robust early-stage endpoints.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of neuropsychiatric assets.
Implementation Considerations
- Requires expertise in TMS, EEG, and neuronavigation for accurate data acquisition.
- Demands high-quality instrumentation and analytical infrastructure for artifact minimization and signal fidelity.
- Necessitates rigorous cross-team standardization of electrode placement and stimulation parameters.
- Adaptation across cortical targets may require protocol optimization for each brain region.
- Artifact removal processes may inadvertently exclude relevant neurophysiological signals.
Biopharma FAQs
Why does null hypothesis testing matter for TMS-EEG target validation?
Null hypothesis testing in TMS-EEG protocols enables objective evaluation of whether observed neurophysiological changes are attributable to intervention rather than background variability. This statistical rigor is essential for establishing target engagement and predictive biomarker validity in early-stage neuropsychiatric R&D.
How does independent variable isolation fit the TMS-EEG discovery pipeline?
Isolating stimulation parameters and cortical targets in TMS-EEG studies ensures that measured changes in excitability or connectivity are specifically linked to the intervention under investigation. This isolation supports mechanistic de-risking and strengthens the interpretability of neurophysiological endpoints.
What do quantitative dependent variable measurements enable in TMS-EEG?
Quantitative EEG and TMS-evoked response measurements provide reproducible, objective data on cortical excitability and connectivity, enabling comparison across conditions, interventions, and timepoints. These outputs are critical for predictive biomarker development and cross-study integration.
Why are replication requirements important for cross-functional TMS-EEG collaboration?
Replication of TMS-EEG results across sessions and teams ensures reliability and generalizability of neurophysiological findings, facilitating cross-functional collaboration and data integration in multi-site or multi-program R&D environments.
What statistical analysis capabilities are required before TMS-EEG implementation?
Robust statistical analysis is required to distinguish true neurophysiological effects from artifacts and noise, including thresholding for motor-evoked potentials and topographical mapping of EEG responses. These capabilities underpin reliable interpretation and decision-making in biopharma pipelines.
